Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare glucose pharmacokinetics and insulin pharmacodynamics injected via the MicronJet in comparison with a conventional needle.


Clinical Trial Description

Administration of insulin to the skin has many potential advantages including improved kinetics and reduced pain. Today, insulin is injected to the SQ space, using, in most cases, various devices incorporating standard metal needles and usually causing considerable pain and discomfort to the patients. NanoPass has developed a microneedle based needle substitute for intradermal injections. This device requires minimal expertise and is expected to cause minimal or no pain during injections.

The objective of this study is to compare the pharmacokinetics and pharmacodynamics of insulin Novorapid® (Novo Nordisk) injected via the MicronJet device intradermally, to a conventional needle injected to the SQ space. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT00602914
Study type Interventional
Source NanoPass Technologies Ltd
Contact
Status Completed
Phase Phase 0
Start date March 2008
Completion date July 2009

See also
  Status Clinical Trial Phase
Completed NCT04505319 - Clinical Evaluation of the Safety and Performance of a Filler in Correction of Mid-face Age-related Volume Deficit N/A
Completed NCT00539084 - A Study to Assess the Safety and Efficacy of a Microneedle Device for Local Anesthesia N/A